 CAMBRIDGE, Mass., July 08, 2021 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq: VOR or the Company, a cell therapy company pioneering engineered hematopoietic stem cell eHSC therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with Janssen Biotech, Inc. Janssen, one of the Janssen Pharmaceutical Companies of Johnson Johnson. The agreement was facilitated by Johnson Johnson Innovation. 